

# Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/MBFAD62F27EEN.html>

Date: June 2020

Pages: 92

Price: US\$ 2,000.00 (Single User License)

ID: MBFAD62F27EEN

## Abstracts

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple System Atrophy - Pipeline Review, H1 2020, provides an overview of the Multiple System Atrophy (Central Nervous System) pipeline landscape.

Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs body's involuntary functions (blood pressure, heart rate, bladder function and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple System Atrophy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Multiple System Atrophy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple System Atrophy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or

Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5, 8 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Multiple System Atrophy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple System Atrophy (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Multiple System Atrophy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Multiple System Atrophy (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Multiple System Atrophy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Multiple System Atrophy (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Multiple System Atrophy (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Multiple System Atrophy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Overview

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Companies Involved in Therapeutics Development

1st Bio Therapeutics Inc

Alterity Therapeutics Ltd

Arvinas Inc

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

Corestem Inc

Denali Therapeutics Inc

EmeraMed Ltd

ICB International Inc

Inhibikase Therapeutics Inc

Ionis Pharmaceuticals Inc

MitoDys Therapeutics Ltd

Modag GmbH

Neuropore Therapies Inc

Newron Pharmaceuticals SpA

ProMIS Neurosciences Inc

Stealth BioTherapeutics Corp

United Neuroscience Ltd

Voyager Therapeutics Inc

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Drug Profiles

1ST-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AHT-434 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anle-138b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Alpha Synuclein for Parkinson's Disease and Multiple System

Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIIB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-10BR05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emeramide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapies to Inhibit SNCA for Neurology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IkT-148X - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ION-464 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Alpha Synuclein for Multiple System Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSA-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-20011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

saquinamide mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBT-272 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Alpha Synuclein for Multiple System Atrophy and Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Neurodegenerative Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UB-312 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

verdiperstat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)  
- Dormant Projects

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)  
- Product Development Milestones

Featured News & Press Releases

May 20, 2020: Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

Mar 18, 2020: Biohaven's Verdiperstat receives fast track designation for the treatment of multiple system atrophy

Jan 14, 2020: European Commission approves Orphan Designation for Alterity's lead drug candidate

Dec 18, 2019: MODAG initiates first-in-human phase 1 clinical trial for Anle138b

Nov 18, 2019: Alterity's lead drug candidate receives positive opinion from European medical agency

Oct 17, 2019: Arvinas to Present update on Small Molecule to Inhibit Alpha Synuclein for Multiple System Atrophy and Parkinson's Disease at the 2nd Targeted Protein Degradation Summit

Sep 25, 2019: Alterity presents clinical data on PBT434 at the 2019 MDS Congress

Aug 01, 2019: Biohaven initiates enrolment in verdiperstat's study for MSA

Jul 29, 2019: Alterity Therapeutics announces successful completion of phase 1 clinical trial

May 07, 2019: Biohaven provides update on verdiperstat from its MPO platform

May 06, 2019: Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting

May 03, 2019: Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting

Apr 10, 2019: Alterity Therapeutics launches to Asian investors

Feb 19, 2019: Biohaven's Verdiperstat receives Orphan Drug Designation From FDA For multiple system atrophy

Jan 31, 2019: Prana receives Orphan Designation for PBT434 for treatment of MSA



Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by 1st Bio Therapeutics Inc, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by Alterity Therapeutics Ltd, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by Arvinas Inc, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by Biogen Inc, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by Corestem Inc, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by Denali Therapeutics Inc, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by EmeraMed Ltd, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by ICB International Inc, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by Inhibikase Therapeutics Inc, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by Ionis Pharmaceuticals Inc, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by MitoDys Therapeutics Ltd, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by Modag GmbH, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by Neuropore Therapies Inc, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by Newron Pharmaceuticals SpA, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by ProMIS Neurosciences Inc, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by Stealth BioTherapeutics Corp, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by United Neuroscience Ltd, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Pipeline by Voyager Therapeutics Inc, H1 2020

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Dormant Projects, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

1st Bio Therapeutics Inc

Alterity Therapeutics Ltd

Arvinas Inc

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

Corestem Inc

Denali Therapeutics Inc

EmeraMed Ltd

ICB International Inc

Inhibikase Therapeutics Inc

Ionis Pharmaceuticals Inc

MitoDys Therapeutics Ltd

Modag GmbH

Neuropore Therapies Inc

Newron Pharmaceuticals SpA

ProMIS Neurosciences Inc

Stealth BioTherapeutics Corp

United Neuroscience Ltd

Voyager Therapeutics Inc

## I would like to order

Product name: Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/MBFAD62F27EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MBFAD62F27EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

